ID   HCC827/WR
AC   CVCL_DG26
DR   cancercelllines; CVCL_DG26
DR   Wikidata; Q54881807
RX   PubMed=26980747;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:61400; WZ4002.
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2063 ! HCC827
SX   Female
AG   39Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 12
//
RX   PubMed=26980747; DOI=10.18632/oncotarget.8013;
RA   Park J.H., Choi Y.J., Kim S.Y., Lee J.-E., Sung K.J., Park S.,
RA   Kim W.S., Song J.S., Choi C.-M., Sung Y.H., Rho J.K., Lee J.C.;
RT   "Activation of the IGF1R pathway potentially mediates acquired
RT   resistance to mutant-selective 3rd-generation EGF receptor tyrosine
RT   kinase inhibitors in advanced non-small cell lung cancer.";
RL   Oncotarget 7:22005-22015(2016).
//